Literature DB >> 11137047

Hepatitis C virus and interferon resistance.

D R Taylor1, S T Shi, M M Lai.   

Abstract

Interferon plays a critical role in the host's natural defense against viral infections and in their treatment. It is the only therapy for hepatitis C virus (HCV) infection; however, many virus isolates are resistant. Several HCV proteins have been shown to possess properties that enable the virus to evade the interferon-mediated cellular antiviral responses.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11137047     DOI： 10.1016/s1286-4579(00)01329-0

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  13 in total

1.  Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA.

Authors:  Jashmin Vyas; Androulla Elia; Michael J Clemens
Journal:  RNA       Date:  2003-07       Impact factor: 4.942

2.  Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism.

Authors:  Jonathan Goldwasser; Pazit Y Cohen; Wenyu Lin; Danny Kitsberg; Patrick Balaguer; Stephen J Polyak; Raymond T Chung; Martin L Yarmush; Yaakov Nahmias
Journal:  J Hepatol       Date:  2011-02-24       Impact factor: 25.083

3.  Quantitative analysis of interferon alpha receptor subunit 1 and suppressor of cytokine signaling 1 gene transcription in blood cells of patients with chronic hepatitis C.

Authors:  Virginia Sedeño-Monge; Gerardo Santos-López; Rosa C Rocha-Gracia; Daniel Meléndez-Mena; Alberto Ramírez-Mata; Verónica Vallejo-Ruiz; Julio Reyes-Leyva
Journal:  Virol J       Date:  2010-09-18       Impact factor: 4.099

4.  SH2 modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells.

Authors:  Bret Poat; Sidhartha Hazari; Partha K Chandra; Feyza Gunduz; Luis A Balart; Xavier Alvarez; Srikanta Dash
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

5.  Inhibition of hepatitis C virus replication by arsenic trioxide.

Authors:  Der-Ren Hwang; Yuan-Chin Tsai; Jin-Ching Lee; Kuo-Kuei Huang; Ren-Kuo Lin; Chia-Hua Ho; Jeng-Min Chiou; Ying-Ting Lin; John T A Hsu; Chau-Ting Yeh
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

6.  Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.

Authors:  Celia Perales; Nathan M Beach; Isabel Gallego; Maria Eugenia Soria; Josep Quer; Juan Ignacio Esteban; Charles Rice; Esteban Domingo; Julie Sheldon
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

7.  Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.

Authors:  Svetlana Radaeva; Barbara Jaruga; Won-Ho Kim; Theo Heller; T Jake Liang; Bin Gao
Journal:  Biochem J       Date:  2004-04-01       Impact factor: 3.857

8.  Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling.

Authors:  Kattareeya Kumthip; Pattranuch Chusri; Nikolaus Jilg; Lei Zhao; Dahlene N Fusco; Hong Zhao; Kaku Goto; Du Cheng; Esperance A Schaefer; Leiliang Zhang; Chansom Pantip; Satawat Thongsawat; Amornrat O'Brien; Lee F Peng; Niwat Maneekarn; Raymond T Chung; Wenyu Lin
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

9.  The genotype analysis of the hepatitis C virus in Heilongjiang Province, China.

Authors:  Xue-Di Cheng; Hua-Feng Xu; Feng Wei; Li-Xin Jiang; Hai-Zhou Zhou
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

10.  Intracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication.

Authors:  Bret Poat; Sidhartha Hazari; Partha K Chandra; Feyza Gunduz; Xavier Alvarez; Luis A Balart; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2010-10-12       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.